Insider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Sells $106,599.15 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach sold 33,841 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $106,599.15. Following the completion of the sale, the chief executive officer now directly owns 7,029,674 shares of the company’s stock, valued at approximately $22,143,473.10. This trade represents a 0.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Puma Biotechnology Stock Performance

Puma Biotechnology stock opened at $2.95 on Monday. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. The firm has a market cap of $144.81 million, a P/E ratio of 6.15 and a beta of 1.10. Puma Biotechnology, Inc. has a 1-year low of $2.22 and a 1-year high of $7.73. The firm has a 50-day moving average of $2.99 and a 200-day moving average of $2.97.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.10. The business had revenue of $80.50 million during the quarter, compared to analysts’ expectations of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same quarter last year, the business posted $0.12 EPS. Sell-side analysts expect that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

Institutional Trading of Puma Biotechnology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PBYI. Rice Hall James & Associates LLC raised its holdings in Puma Biotechnology by 3.3% in the 2nd quarter. Rice Hall James & Associates LLC now owns 144,792 shares of the biopharmaceutical company’s stock worth $472,000 after purchasing an additional 4,686 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its position in shares of Puma Biotechnology by 72.7% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 8,000 shares during the period. Royce & Associates LP raised its stake in Puma Biotechnology by 71.8% in the third quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 8,427 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in Puma Biotechnology by 17.7% in the second quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 10,757 shares during the period. Finally, SG Americas Securities LLC bought a new stake in Puma Biotechnology during the 3rd quarter valued at approximately $34,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Wall Street Analyst Weigh In

PBYI has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research note on Monday, December 23rd. StockNews.com downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.